The Form 4 filing, which reports insider stock trades, was filed on November 13, 2026. It covers trades made on November 11, 2026, by Jack Anders, chief financial officer of Revolution Medicines (RVMD).
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-11 |
| Date of Latest Transaction | 2026-11-11 |
| Buy/Sell | sell |
| Transaction Count | 11 |
| Shares Transacted | 35,750 |
| Price | $188.10 |
| Total Transaction Value | $6,724,687.85 |
| Insider | |
| Ticker Symbol | RVMD |
| Company | Revolution Medicines, Inc. |
| Insider Name | Anders Jack |
| Insider Title | Chief Financial Officer |
| Sector - Industry | Healthcare - Biotechnology |
| Holdings | |
| Total Shares Owned After Transaction | 119,216 |
| Position Size Change | 23.07% |
| Filing | |
| Filing Date | 2026-11-13 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
These were share sales, marked with transaction code S. The report covers 11 sale transactions by one insider.
What was the average price of the transaction?
The average sale price was $188.10 per share, rounded to cents. That average covers all 11 sales; individual transaction prices are not available here.
How did this transaction affect the insider's holdings?
Jack Anders sold 35,750 shares and reported 119,216 shares owned afterward. The sales represented 23.07% of the shares he owned before these transactions.
What's the total transaction value?
The total sale value was $6,724,687.8475 before rounding, or $6,724,687.85 to the nearest cent. This total covers all 11 transactions.
Are there any special circumstances around this transaction?
The available transaction information points to a Rule 10b5-1 trading plan. Such plans set trading instructions in advance. Footnote text and plan details are unavailable here, so it is unclear which of the 11 sales the plan reference covers. The plan's start date and trading schedule are also unknown. The reference alone does not show whether the plan met the rule's legal requirements.
For research purposes only; not investment advice.